Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 27, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

NCT06561360
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Vemurafenib, Obinutuzumab, Cladribine, Rituximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Mechanisms of Asthma

NCT00595153
View directory record Official record
Conditions
Asthma
Interventions
Pulmicort
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT00193154
View directory record Official record
Conditions
Kidney Cancer
Interventions
OSI-774, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Results available

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

NCT00582166
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Ibritumomab Tiuxetan (Zevalin) + Rituximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

NCT00542451
View directory record Official record
Conditions
Breast Cancer, Carcinoma of the Breast
Interventions
Paclitaxel, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
20
States / cities
San Francisco, California • Maywood, Illinois • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

NCT01414205
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Obinutuzumab, Corticosteroids
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers

NCT01814709
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0032, Itraconazole, Rifampin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

NCT00529503
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Interventions
SGN-40, placebo, rituximab, etoposide, carboplatin, ifosfamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

NCT00222469
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
bevacizumab, gemcitabine, oxaliplatin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

NCT03625505
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Venetoclax, Gilteritinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

NCT02748642
View directory record Official record
Conditions
Mild Atopic Asthma
Interventions
BITS7201A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 27, 2026, 1:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Drug · Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

NCT03807739
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0134 F09 Formulation, GDC-0134 F15 Formulation, GDC-0134 F16 Formulation
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

NCT03555253
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Resilience-Based Program for Support Partners of PwMS
Behavioral
Lead sponsor
Healios Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Flemington, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Results available

PR3-AAV Resilient Remission or PRRR

NCT05376319
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
Interventions
Obinutuzumab, Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

NCT00459901
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Erlotinib and capecitabine
Drug
Lead sponsor
Peter Kozuch
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 27, 2026, 1:34 PM EDT
Completed No phase listed Observational

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

NCT00096928
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
182
States / cities
Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

NCT00799773
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 27, 2026, 1:34 PM EDT
Not listed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

NCT00262067
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bevacizumab, Placebo, Chemotherapy
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
5
States / cities
Fullerton, California • Santa Barbara, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

NCT00887809
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
Interventions
gemcitabine, docetaxel, bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

NCT00500539
View directory record Official record
Conditions
Asthma
Interventions
omalizumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Palmdale, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

NCT00565487
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Tarceva
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 27, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lucentis for Treatment of Macular Edema

NCT00464581
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 27, 2026, 1:34 PM EDT